VJOncology is committed to improving our service to you

ASCO 2020 | Advances in recurrent endometrial cancer: adavosertib, a WEE1 inhibitor

VJOncology is committed to improving our service to you

Ursula Matulonis

Ursula Matulonis, MD, Dana-Farber Cancer Institute, Boston, MA evaluates advances in recurrent endometrial cancer treatment and highlights the development of adavosertib, a WEE1 inhibitor that shows over a 30% response rate and represents an additional therapy for patients with recurrent endometrial cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter